Amdl Inc - Current report filing (8-K)
October 15 2007 - 6:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
Date of Report (Date of Earliest Event Reported):
|
|
October 12, 2007
|
AMDL, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
0-27689
|
33-0413161
|
_____________________
(State or other jurisdiction
|
_____________
(Commission
|
______________
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
2492 Walnut Avenue, Suite 100, Tustin, California
|
|
92780
|
_________________________________
(Address of principal executive offices)
|
|
___________
(Zip Code)
|
|
|
|
Registrants telephone number, including area code:
|
|
714-505-4461
|
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On October 12, 2007 the Company filed a new application with the U.S. FDA under Section 510(k) of the Food, Drug and Cosmetic Act along with new statistical data to obtain approval to market DR-70 in the United States as an aid in monitoring patients with colorectal cancer. The nature and timing of the FDA's response to the Company's submission of the application cannot be anticipated, nor can there be any assurance that the FDA will clear DR-70 for use in the United States.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
99.1 Press Release announcing the filing of the application with the FDA on October 12, 2007.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
AMDL, Inc.
|
|
|
|
|
|
October 12, 2007
|
|
By:
|
|
/s/Gary L. Dreher
|
|
|
|
|
|
|
|
|
|
Name: Gary L. Dreher
|
|
|
|
|
Title: Chief Executive Officer
|
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release to be issued October 15, 2007
|
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024